問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chiayi Chang Gung Memorial Hospital of the C.G.M.F.

  • 0

    Total Beds

  • 0

    Total Doctors

  • 613Chiayi CountyChiayi Puzih

Recruiting Trial

58Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

190Cases

2014-08-08 - 2018-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2012-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2011-10-01 - 2014-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2009-12-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2007-06-30 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2011-07-01 - 2016-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2020-06-30 - 2023-12-12

Phase III

A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Intermediate-stage Hepatocellular Carcinoma (HCC)

  • Test Drug

    Ipilimumab (5mg/mL; 40 ml)、 nivolumab (10mg/mL; 10 ml)

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

2013-08-01 - 2017-12-31

Phase III

A Randomized, Double-blind, Parallel Group Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride (0.5mg) and Tamsulosin (0.2mg) With Tamsulosin (0.2mg) Monotherapy, Administered Once Daily for 2 Years, on the Improvement of Symptoms and Health Outcomes in Men With Moderate to Severe Benign Prostatic Hyperplasia

  • Condition/Disease

    Moderate to Severe Benign Prostatic Hyperplasia

  • Test Drug

    (1) AVODART SOFT CAPSULES；(2) Harnalidge D tablets

Participate Sites
8Sites

Not yet recruiting1Sites

Terminated7Sites

鄭鴻琳
National Taiwan University Hospital

Division of Urology

2015-02-25 - 2025-12-31

Phase III

A PHASE III PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ADJUVANT MEDI4736 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER

  • Condition/Disease

    COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER

  • Test Drug

    MEDI4736

Participate Sites
13Sites

Not yet recruiting2Sites

Recruiting3Sites

Terminated8Sites

2010-03-06 - 2011-09-27

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

1 15 16 17 18 19
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB